Literature DB >> 3032463

Regulation of human peripheral blood monocyte collagenase by prostaglandins and anti-inflammatory drugs.

L M Wahl, L L Lampel.   

Abstract

Macrophages, which produce the collagenolytic enzyme collagenase, are commonly found at sites of connective tissue destruction in chronic inflammatory lesions. Since tissue macrophages are derived from circulating peripheral blood monocytes, we used these less-differentiated, more readily available cells to examine the production and regulation of collagenase. Human monocytes, isolated in large quantities by counterflow centrifugal elutriation, were shown to produce substantial amounts of collagenase when stimulated by concanavalin A (Con A) and to a lesser extent with lipopolysaccharide, while unstimulated monocyte cultures produced negligible collagenase. Collagenase was detected in the culture media within the first 24 hr of culture after activation with peak production at 48 hr. Analysis of the intracellular regulation of collagenase revealed that synthesis of this enzyme required a prostaglandin (PGE2)-dependent step since indomethacin-inhibited enzyme synthesis was reversed by PGE2. Additionally, dibutyryladenosine cyclic monophosphate (dBcAMP) restored collagenase synthesis in indomethacin-blocked cultures, indicating a PGE2-dependent generation of cAMP requirement for collagenase production similar to that demonstrated in experimental animals systems. In additional studies, anti-inflammatory drugs which are known to modulate connective tissue destruction were analyzed for their influence on monocyte-derived collagenase. Dexamethasone, colchicine or retinoic acid all inhibited collagenase synthesis by monocytes in a dose-dependent manner although the effect of these drugs on monocyte PGE2 synthesis differed. Dexamethasone inhibited PGE2 synthesis, which resulted in the suppression of collagenase. However, PGE2 production was unaffected by colchicine whereas retinoic acid caused a significant increase in PGE2 levels. Inhibition of collagenase synthesis by dexamethasone, but not colchicine or retinoic acid, could be reversed by PGE2 or phospholipase A2. These findings provide insight into the intracellular events regulating monocyte collagenase synthesis and also implicate monocytes as a target of anti-inflammatory agents which ameliorate connective tissue degradation associated with chronic inflammatory lesions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3032463     DOI: 10.1016/0008-8749(87)90088-8

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  6 in total

1.  Monocyte macrophage differentiation in vitro: Fibronectin-dependent upregulation of certain macrophage-specific activities.

Authors:  P R Sudhakaran; A Radhika; S S Jacob
Journal:  Glycoconj J       Date:  2007-01       Impact factor: 2.916

2.  Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases.

Authors:  Y Zhang; D L DeWitt; T B McNeely; S M Wahl; L M Wahl
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

3.  Modulation of macrophage protease activity by acute administration of O,O,S trimethyl phosphorothioate.

Authors:  K E Rodgers; D D Ellefson
Journal:  Agents Actions       Date:  1990-03

4.  Interleukin-4 suppression of interleukin-1-induced transcription of collagenase (MMP-1) and stromelysin 1 (MMP-3) in human synovial fibroblasts.

Authors:  R C Borghaei; P L Rawlings; E Mochan
Journal:  Arthritis Rheum       Date:  1998-08

5.  Prostaglandin H synthase isoenzyme distribution in the gingival tissue of patients with periodontitis: pronounced expression adjacent to gram-positive bacteria.

Authors:  J S McDonald; P F Cavanaugh; L J Pavelic; R J Limardi; J L Gluckman; Z P Pavelic
Journal:  Inflammopharmacology       Date:  1997       Impact factor: 4.473

Review 6.  The role of microglia and matrix metalloproteinases involvement in neuroinflammation and gliomas.

Authors:  Helen Könnecke; Ingo Bechmann
Journal:  Clin Dev Immunol       Date:  2013-08-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.